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Biomarkers based on functional signaling have the potential to provide greater insight into the pathogen-
esis of cancer and may offer additional targets for anticancer therapeutics. Here, we identiﬁed hepatoma-
derived growth factor-related protein-3 (HRP-3) as a radioresistance-related gene and characterized the
molecular mechanism by which its encoded protein regulates the radio- and chemoresistant phenotype
of lung cancer-derived A549 cells. Knockdown of HRP-3 promoted apoptosis of A549 cells and potenti-
ated the apoptosis-inducing action of radio- and chemotherapy. This increase in apoptosis was associated
with a substantial generation of reactive oxygen species (ROS) that was attributable to inhibition of the
Nrf2/HO-1 antioxidant pathway and resulted in enhanced ROS-dependent p53 activation and p53-depen-
dent expression of PUMA (p53 upregulated modulator of apoptosis). Therefore, the HRP-3/Nrf2/HO-1/
ROS/p53/PUMA cascade is an essential feature of the A549 cell phenotype and a potential radiotherapy
target, extending the range of targets in multimodal therapies against lung cancer.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. 1. Introduction
Hepatoma-derived growth factor (HDGF) was initially puriﬁed
as a secreted mitogen from the Huh-7 human hepatoma cell lines
[1]. HDGF is a nuclear protein with mitogenic activity that func-
tions as a transcriptional repressor by binding to a conserved ele-
ment in the promoter of target genes [2]. Recently, HDGF has
been found to be a potent tumorigenic and prognostic factor in
cancers, including hepatocellular carcinoma (HCC), gastric cancer,
and non-small-cell lung cancer (NSCLC). For example, overexpres-
sion of HDGF is correlated with promotion of lymph node metasta-
ses in gastric cancer [3]. Despite the accumulated knowledge about
the biochemical functions of HDGF protein, its signaling mecha-
nisms in development, vascular injury, and cancer are still largely
unknown.Currently, ﬁve HDGF-related proteins (HRPs) have been identi-
ﬁed from different species, including HRP-1 to -4 and lens epithe-
lium-derived growth factor (LEDGF), all of which share a conserved
DNA-binding HATH domain at the N-terminus [4]. Studies on HRP
expression in mouse and bovine models have reported that both
HRP-1 and HRP-4 mRNA expression are limited to the testis,
whereas HRP-2 transcripts are more broadly distributed [4,5].
Although HRP-3 mRNA is expressed to a slight extent in the ovary,
kidney, spleen, and liver, it is mainly restricted to the brain in hu-
mans, suggesting a particular role in the nervous system [6]. Con-
sistent with this, HRP-3 expression in the brain is regulated in a
developmental stage-dependent manner in mice and has biological
roles beyond growth-promoting activity in the brain [7]. For exam-
ple, HRP-3 is involved in neuritogenesis of primary cortical neu-
rons through modulation of the neuronal cytoskeleton by
interacting with tubulin [8] or heparin sulfate proteoglycans [9].
One recent study has reported an association of HRP-3 with cancer
[10]. The authors of this study suggested that HRP-3 plays an
essential role in the pathogenesis of HCC based on the signiﬁcant
upregulation of HRP-3 in human HCC tissues compared to non-
cancerous tissues. Although HRP-3 signaling has been implicated
in the physiology of neuronal cells, its pathological relevance in
NSCLC cells and associated molecular mechanisms of action
remain largely unknown. In particular, the role of HRP-3 in the
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agents by these cells remains unclear.
Here, we demonstrate that HRP-3 knockdown using small inter-
fering RNA (siRNA) promoted apoptosis of radio- and chemoresis-
tant A549 cells and signiﬁcantly sensitized these cells to
radiotherapy- and chemotherapy-induced apoptosis. Consistent
with this, HRP-3 depletion alone or in combination with radiation
markedly increased the generation of reactive oxygen species
(ROS) via inhibition of the Nrf2 (nuclear factor erythroid 2 related
factor 2)/HO-1 (heme oxygenase 1) pathway. Elevated ROS levels,
in turn, contributed to apoptosis by enhancing ROS–dependent
p53 activation and expression of PUMA (p53 upregulated modula-
tor of apoptosis). Disruption of HRP-3 thus reveals an important
role of the HRP-3/Nrf2/HO-1/ROS/p53/PUMA cascade in promoting
apoptosis of A549 cells and suggests that HRP-3 may serve as a no-
vel molecular target for the development of new agents for lung
cancer therapy.
2. Materials and methods
2.1. Cell culture and treatment
Human A549 and H460 cells were purchased from the ATCC
(Manassas, VA, USA) and cultured in RPMI-1640 medium supple-
mented with 10% fetal bovine serum. Cells were irradiated using
a 137Cs-ray source (Atomic Energy of Canada, Ltd., Mississauga,
Canada) at a dose rate of 3.81 Gy/min. Where indicated, cells were
treated with 0.1 lg/mL doxorubicin or 5 ng/mL vinblastine to in-
duce apoptosis. We used 1 mM N-acetyl cysteine (NAC) to scav-
enge ROS and 10 lM cycloheximide to block de novo protein
synthesis. All chemicals were obtained from Sigma–Aldrich (St.
Louis, MO, USA).
2.2. Cell proliferation
HRP-3-knockdown and control cells were plated on culture
dishes at a density of 3.5  105 cells/cm2 for the indicated times.
Cell proliferation was determined by directly counting surviving
cells using a hemocytometer.
2.3. Clonogenic assay
Cell survival was determined using clonogenic assays, as de-
scribed previously [11].
2.4. Cell death assay
Cell death was quantiﬁed as described previously [12]. Apopto-
tic cell death was also determined by Western blot analysis of
cleaved poly (ADP–ribose) polymerase (PARP) and activated cas-
pase-3. Alterations in cellular morphology were observed by light
microscopy.
2.5. ROS assay
Cells were incubated with 10 nM 20,70-dichloroﬂuorescein diac-
etate (Molecular Probes, Inc., Eugene, OR, USA) for 20 min and ana-
lyzed by ﬂuorescence-activated cell sorting (FACS) to detect ROS,
as described previously [12].
2.6. Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR was performed as previously described [12]. The follow-
ing primer pairs were employed: HRP-3 (426-bp product), 50-
ATGAAGGGCTACCCGCACTG-30 (sense) and 50-CCGGGACTGTTTAGAGGATTTC-30 (antisense); p53 (361-bp product), 50-GTGGTG
CCCTATGAGCCGCC-30 (sense) and 50-GCTCACGCCCACGGATCTGA-
30 (antisense); and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (305-bp product), 50-CATCTCTGCCCCCTCTGCTGA-30
(sense) and 50-GGATGACCTTGCCCACAGCCT-30 (antisense). Quanti-
tative real-time PCR was performed in triplicate using a Chromo4
thermocycler and SYBR Premix Ex Taq (Takara Bio, Shiga, Japan).
The ampliﬁcation signal of the target gene was normalized to that
of GAPDH in the same reaction.
2.7. Knockdown of HRP-3 by siRNA
The following siRNA oligonucleotides targeting HRP-3 were
synthesized by Genolution Pharmaceuticals, Inc (Seoul, Korea):
siRNA #1, 50-CCAGUGAAGGGACCUAACUUU-30 (sense) and 50-AGU-
UAGGUCCCUUCACUGGUU-30 (antisense); siRNA #2, 50-GGCCAU-
GUGUAAAGUUUAAUU-30 (sense) and 50-UUAAACUUUACACAUGG
CCUU-30 (antisense). Non-silencing siRNA was used as a negative
control. In experiments, cells were transfected with siRNA #2 as
described previously [11].
2.8. Western blot analysis
Western blot analyses were performed as described previously
[12] using primary antibodies against HRP-3 (Proteintech Group,
Inc., Chicago, IL, USA); p53 and Nrf2 (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA); Keap1 (R&D Systems, Inc., Minneapolis,
MN, USA); and cleaved-PARP (Asp214), cleaved caspase-3, phos-
pho-p53 (Ser15), PUMA, and HO-1 (Cell Signaling Technology
Inc., Beverly, MA, USA). b-Actin (Sigma) was used as a loading
control.
2.9. Immunoﬂuorescence confocal microscopy
For staining, cells were incubated for 1 h with 10 lg/ml of rab-
bit polyclonal anti-HRP-3 primary antibody (Proteintech Group,
Inc.) and then incubated for an additional 1 h with ﬂuorescein iso-
thiocyanate-conjugated secondary antibody (Invitrogen, Carlsbad,
CA, USA), as described previously [11].
2.10. Statistical analysis
Cell culture experiments were repeated at least three times.
Statistical differences between groups were assessed by Students
t-test, and a p-value <0.05 was considered signiﬁcant.
3. Results
3.1. Depletion of HRP-3 induces apoptosis of radio- and
chemoresistant A549 cells
Individual treatment of A549 cells with radiation, doxorubicin,
or vinblastine induced approximately 17%, 16% and 19% cell death,
respectively, compared to the corresponding values of 41%, 38%
and 43% in H460 cells (Fig. 1A), suggesting that A549 cells were
more tolerant to radiation and the anticancer drugs than H460
cells. To identify genes that contributed to the radioresistant cellu-
lar phenotype, we screened lung cancer EST libraries (#1611) for
resistance-related genes using an in silico/in vitro analysis. Among
the radiation-responsive genes identiﬁed by these screens was that
for HRP-3 gene. Notably, the transcript (Fig. 1B, top) and protein
(Fig. 1B, bottom) levels of HRP-3 were much higher in A549 cells
than in H460 cells, supporting the association of HRP-3 with the
radioresistant phenotype of A549 cells. Immunoﬂuorescence stain-
ing analyses revealed that HRP-3 was distributed only in the
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Fig. 1. Association of HRP-3 with the resistant phenotype of A549 cells. (A) H460 and A549 cells were treated with 10 Gy radiation, 0.1 lg/mL doxorubicin, or 5 ng/mL
vinblastine for 48 h. Cell death was determined by FACS analysis; data are expressed as means ± SD (⁄p < 0.05, ⁄⁄p < 0.005, and ⁄⁄⁄p < 0.0005 compared with untreated
controls). (B) Transcript (top) and protein (bottom) levels of HRP-3 in H460 and A549 cells were determined by RT-PCR (loading control, GAPDH) and Western blotting,
respectively. (C) Representative confocal images of HRP-3 localization in H460 and A549 cells (scale bar: 50 lm). (D–F) A549 cells were transfected with or without 100 nM
HRP-3 siRNA for 5 h and then cultured for an additional 4 days (D), 2 days (E), or 14 days (F). Proliferation was determined by cell counting; data are expressed as means ± SD
(⁄p < 0.05 and ⁄⁄p < 0.005 compared with untransfected control) (D). Changes in cell morphology were observed by light microscopy (E, left; scale bar: 1 mm) and cell death
was determined by FACS analysis; data are expressed as means ± SD (⁄⁄p < 0.005 compared with untransfected control) (E, right). Colony formation was visualized by trypan
blue staining (F, left); data are expressed as means ± SD (⁄⁄⁄p < 0.0005 compared with untransfected control) (F, right).
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presumptive primary role in nuclear signal transduction (Fig. 1C).
To examine whether HRP-3 is a key factor in maintaining the resis-
tant phenotype of A549 cells, we knocked downed endogenous
HRP-3 by transfecting A549 cells with two different siRNAs.
Although both siRNAs markedly decreased HRP-3 expression, siR-
NA #2 was more effective, as determined by quantitative RT-PCR
and Western blotting (Supplemental Fig. 1A and B). Thus, subse-
quent knockdown experiments were performed using siRNA #2.
Depletion of HRP-3 potently reduced proliferation of A549 cells
in a time-dependent fashion compared to control cells (Fig. 1D)
and induced morphological changes characteristic of apoptosis in
approximately 17% of cells compared to 7% in controls (Fig. 1E).
In support of these results, the levels of cleaved PARP and active
caspase-3, two important apoptotic standards, were elevated in
HRP-3-knockdown cells compared to control cells transfected with
scrambled siRNA (Supplemental Fig. 1C). In addition, siRNA-medi-
ated HRP-3 knockdown decreased colony formation by approxi-
mately 53% compared to control cells (Fig. 1F). Thus, our results
suggest that HRP-3 is essential for the maintenance of the radio-
and chemoresistant phenotype of A549 cells.
3.2. HRP-3 depletion synergistically induces apoptosis of A549 cells in
combination with radiation or anticancer drugs
To examine whether HRP-3 is involved in responses to radiation
or anticancer drugs, we treated A549 cells with 10 Gy radiation,0.1 lg/mL doxorubicin, or 5 ng/mL vinblastine. All stimulations in-
creased HRP-3 protein levels, which reached a peak at about 24 h
and then declined to basal levels (Fig. 2A), indicating that HRP-3
is a radiation- and anticancer drug-responsive protein. To better
understand the correlation between HRP-3 level and resistant phe-
notype, we analyzed the effect of HRP-3 loss-of-function in A549
cells exposured to the same stimuli. Although siHRP-3 alone in-
duced cell death compared to control siRNA, stimulation with radi-
ation, doxorubicin, or vinblastine signiﬁcantly enhanced cell death
by approximately 2.3-, 2.4-, and 2.3-fold, respectively, in HRP-3-
knockdown cells compared to A549 cells transfected with siHRP-
3 alone (Fig. 2B). This combined effect was especially prominent
in HRP-3-knockdown A549 cells exposed to 6 Gy radiation, where
colony formation was decreased by approximately 74% compared
to A549 cells transfected with siHRP-3 alone (Fig. 2C); clonogenic
survival assays showed that HRP-3-knockdown cells were also
more sensitive than control cells to exposure to single doses of
radiation ranging from 0 Gy to 6 Gy (Fig. 2D). In line with these re-
sults, combined radiation treatment and HRP-3 depletion caused a
signiﬁcant increase in cleaved PARP and active caspase-3 levels,
although each treatment alone induced a slight increase in both
cleaved PARP and active caspase-3 levels compared to control
(Fig. 2E). The levels of these two apoptotic markers also consis-
tently paralleled cell death patterns in A549 cells stimulated with
anticancer drugs and/or siHRP-3 (Fig. 2F). Therefore, our data sug-
gest that HRP-3 is a key regulator of the radio- and chemosensitiv-
ity of A549 cells.
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A549 cells
To identify the mechanisms by which HRP-3 depletion induced
cytotoxicity in A549 cells, we compared the levels of proteins in-
volved in ROS production between H460 and A549 cells. Interest-
ingly, highly HRP-3-expressing A549 cells maintained higher
levels of antioxidant coordinators, notably the transcription factor
Nrf2 and its target HO-1, compared to those of H460 cells; how-
ever, protein levels of Keap-1, a repressor of Nrf2 activation, were
similar in the two cell lines (Fig. 3A). To determine whether HRP-3
directly regulated Nrf2 and HO-1 expressions, we depleted endog-
enous HRP-3 with siRNA and examined the levels of Nrf2 and HO-
1. Depletion of HRP-3 markedly reduced Nrf2 and HO-1 protein
levels without altering Keap-1 expression (Fig. 3B), indicating that
Nrf2 and HO-1 are downstream targets of HRP-3. Because Nrf2/
HO-1 signaling is a key antioxidant pathway that acts as a primary
cellular defense system in response to oxidative stress [13], we
examined the effect of HRP-3 on ROS generation using RNA inter-
ference. siRNA-mediated HRP-3 knockdown in A549 cells induced
a signiﬁcant (1.6-fold) increase in ROS generation compared to
control cells, an increase that was reduced to below basal levels
by treatment with the ROS scavenger NAC (Fig. 3C). Treatment of
A549 cells with radiation alone induced approximately a 1.8-fold
increase in ROS production, compared with untreated control;
combining radiation with HRP-3 depletion signiﬁcantly enhanced
this effect, increasing ROS production by approximately 3.4-foldcompared with controls (Fig. 3D). Thus, our results suggest that
HRP-3 normally acts to positively regulate ROS scavenging via
Nrf2/HO-1 signaling.
3.4. HRP-3 is essential for regulating ROS-dependent, p53-induced cell
death
To further dissect the signaling pathway involved in HRP-3
depletion-induced apoptosis, we focused on the tumor suppressor
protein p53, a transcription factor activated by redox imbalance
and DNA damage [14]. Transfection of A549 cells with HRP-3 siR-
NA led to an increase in the expression and activation of p53 and
also induced expression of PUMA, a key mediator of p53-depen-
dent cell death, compared to controls (Fig. 4A). To conﬁrm the ef-
fect of ROS on p53-mediated cell death, we assessed apoptosis
and monitored the levels of the above proteins after treatment
with NAC. As shown in Fig. 4B, the induction of cleaved PARP by
HRP-3 knockdown was signiﬁcantly decreased by NAC treatment,
suggesting a reduced commitment to apoptosis. Consistent with
this notion, p53 and PUMA levels were also dramatically decreased
by NAC treatment in siHRP-3-transfected A549 cells (Fig. 4B), sug-
gesting that p53 and PUMA accumulation is downstream of ROS
signaling. To determine whether HRP-3 depletion-mediated up-
regulation of p53 protein is due to a posttranslational increase in
p53 stability, we treated control and HRP-3-knockdown A549 cells
with cycloheximide for 1, 2, and 3 h and analyzed p53 protein lev-
els. The p53 exhibited a linear elimination over time, as shown by
HRP-3 
Nrf2
HO-1 
Keap-1 
β-actin
H
46
0
A5
49
A 
B 
HRP-3 
Nrf2
HO-1 
Keap-1 
β-actin
C 
100 101 104 103 102 
0 
20
40
60
80
10
0
FL1-H 
C
ou
nt
siHRP-3 
+NAC 
Scrambled
R
O
S 
ge
ne
ra
tio
n 
(fo
ld
 in
du
ct
io
n)
2.0
1.5
1.0
0.5
0 
siHRP-3    - + + 
NAC    - - + 
* **12
0
siHRP-3 
siHRP-3 
D 
100 101 104 103 102 
0 
40
80
12
0
16
0
FL1-H 
C
ou
nt
siHRP-3 
+Radiation 
Scrambled
R
O
S 
ge
ne
ra
tio
n 
(fo
ld
 in
du
ct
io
n)
4.5
3.0
1.5
0 
siHRP-3    - - + 
Radiation    - +  + 
**
***2
00
Radiation
Fig. 3. HRP-3 knockdown induces ROS generation via inhibition of the Nrf2/HO-1 pathway. (A) Levels of ROS-related proteins in H460 and A549 cells were determined by
Western blotting. (B) A549 cells were transfected without or with 100 nM HRP-3 siRNA for 48 h. Levels of ROS-related proteins were determined by Western blotting. (C)
A549 cells were transfected as in (B) and incubated without or with 1 mM NAC for 48 h. ROS production was assessed by FACS analysis; data are expressed as means ± SD
(⁄p < 0.05 compared with control; ⁄⁄p < 0.005 compared with cells transfected with siHRP-3 alone). (D) A549 cells were transfected as in (B) without or with exposure to 10 Gy
radiation. ROS production was assessed by FACS analysis; data are expressed as means ± SD (⁄⁄p < 0.005 compared with control; ⁄⁄⁄p < 0.0005 compared with cells treated
with radiation alone).
H.S. Yun et al. / Biochemical and Biophysical Research Communications 439 (2013) 333–339 337Western blotting (Fig. 4C, left) and quantitative band-intensity
analysis of Western blots (Fig. 4C, right), and its half-life was short
(<1 h) in control cells and was prolonged (>2 h) in HRP-3-knock-
down cells. Neither cycloheximide nor HRP-3 knockdown affected
the levels of p53 transcript (Fig. 4C, left). The half-life of phosphor-
ylated p53 paralleled that of p53 protein in control A549 cells, but
was signiﬁcantly prolonged (>3 h) in HRP-3-knockdown cells
(Fig. 4C), demonstrating that HRP-3 is involved in regulating p53
activation. Finally, to establish the role of p53 in apoptosis induc-
tion, we treated control and siHRP-3-transfected A549 cells with
radiation. During the process of apoptotic cell death, p53 activation
and PUMA were signiﬁcantly induced in radiation-treated, HRP-3-
knockdown A549 cells compared with untreated or radiation-only
treated control cells (Fig. 4D), conﬁrming that p53 activated in re-
sponse to ROS contributes to apoptotic commitment through its
downstream target PUMA.4. Discussion
Lung cancer is the leading cause of cancer deaths worldwide.
The 5-year survival rate for patients with stage I NSCLC is roughly
60%, but patients with advanced stage NSCLC show very poor sur-
vival rates despite aggressive multimodality treatments [15]. Be-
cause NSCLC patients may receive additional beneﬁt from
adjuvant radiotherapy or chemotherapy following curative surgi-
cal attempts, these adjuvant therapies represent standard practicefor the care of cancer patients. However, many patients suffer
undesirable and potentially treatment-limiting side effects, despite
the beneﬁts of such therapies. Thus, identiﬁcation and application
of novel biomarkers based on an individual patient’s molecular
proﬁle is an unmet need in the therapeutic management of cancer
patients. To this end, we screened for molecules with a signiﬁcant
correlation with the radio- and chemoresistant phenotype of
NSCLC A549 cells and identiﬁed HRP-3.
Although HDGF, a member of the HRP family, is thought to play
a role in the development and progression of numerous human
cancers, including colorectal and liver cancers [16–18], little is
known concerning the role of HRP-3 in cancer beyond a single
study that demonstrated an important role for HRP-3 in HCC path-
ogenesis [10]. This study reported that HRP-3 is highly upregulated
in human HCC tissues compared to normal tissue and showed that
knockdown of HRP-3 sensitized HCC cells to anoikis via activation
of the extracellular signal-regulated kinase pathway. These obser-
vations suggested that HRP-3 could be a target for therapeutic
agents designed to enhance sensitivity to chemotherapy in human
HCC. In the present study, we identiﬁed HRP-3 as a radioresis-
tence- and chemoresistance-related gene in NSCLC A549 cells har-
boring wild-type p53 and characterized the HRP-3-dependent
signaling mechanism that regulates the resistant phenotype of
these cells. Speciﬁcally, we found that depletion of HRP-3 pro-
moted cell death by inducing a substantial increase in intracellular
ROS levels, clearly demonstrating that HRP-3 normally acts
through suppression of ROS to play an essential role in regulating
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cycloheximide for the indicated times. Protein levels of HRP-3, p53, and pp53 were determined by Western blotting and p53 mRNA was detected by RT-PCR (left). The half-
life of proteins is presented graphically; data are expressed as means ± SD (⁄⁄p < 0.005 and ⁄⁄⁄p < 0.0005 compared with untransfected control) (right). (D) A549 cells were
transfected as in (A) without or with exposure to 10 Gy radiation for 48 h. Levels of apoptosis-related proteins were detected by Western blotting.
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and may thus promote cancer. Our experiments further showed
that the increase in ROS levels in HRP-3-knockdown A549 cells
was caused by down-regulation of the Nrf2 transcription factor,
which directly affects the homeostasis of ROS by regulating antiox-
idant defense systems via several mechanisms [19]. On the basis of
differential expression patterns and RNAi experiments, we con-
cluded that Keap-1, which participates in the degradation of
Nrf2, was not involved in regulating the HRP-3-dependent ROS sig-
naling mechanism in A549 cells. However, HO1, a downstream tar-
get gene of Nrf2 encoding the antioxidant enzyme heme oxygenase
1, was markedly decreased in HRP-3-knockdown A549 cells, impli-
cating the Nrf2/HO-1 pathway in HRP-3-depletion-mediated intra-
cellular ROS accumulation and cell death. ROS-mediated DNA
damage generated by anticancer agents or radiation has also been
previously shown to activate p53 and upregulate its target PUMA
to play a critical role in enhancing the cytotoxicity of several cancer
cell types [20]. Consistent with these previous results, the accumu-
lation of ROS induced by HRP-3 knockdown prolonged the half-life
of p53 protein and sustained the active form of p53 in A549 cells.
This maintained active p53 status up-regulated the expression of
PUMA, a pro-apoptotic mediator of p53, in A549 cells, suggesting
that p53 could act through PUMA signaling to produce a loss of
mitochondrial membrane potential and promote apoptosis via
the intrinsic pathway. Notably, however, signaling pathways
downstream of HRP-3 in p53-null or -mutant types of lung
cancer cells remain completely unknown and warrant further
investigation.In conclusion, these studies provide the ﬁrst demonstration that
the HRP-3/Nrf2/HO-1/ROS/p53/PUMA cascade is an essential com-
ponent of intracellular signaling associated with NSCLC pathogen-
esis. Importantly, our ﬁndings establish that the expression of HRP-
3 governs both radioresistance and chemoresistance in NSCLC
cells, suggesting that HRP-3 could serve as a prognostic biomarker
and molecular target for multimodal therapies against NSCLC.
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